Project Grant R21AI183248
Award Date
6/13/24
Completion Date
4/30/26
Dollars Obligated
$334K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94117, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund a $2,353,903 research project to investigate viral and host dynamics during pediatric COVID-19 and respiratory virus co-infections. The primary objectives are to: 1) assess the prevalence of SARS-CoV-2 and respiratory virus co-infections and their association with clinical outcomes; 2) characterize the mucosal immune...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $664,837 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Southern California (USC) Department of Contracts and Grants Division. This 1-year grant, effective from September 1, 2024 to August 31, 2025, will fund research to identify newborns with in-utero SARS-CoV-2 infection and assess associated immunologic factors and clinical outcomes. Key objectives...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $200,016 to The Regents of the University of California, San Francisco (UCSF) over a 5-year period from December 15, 2024 through November 30, 2029.
The funding will support a research program focused on elucidating the specific mechanisms by which certain children develop critical illness from SARS-CoV-2...
This $158,072 project grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to characterize the early childhood neurodevelopmental impact of infants exposed to maternal SARS-CoV-2 infection during pregnancy.
The key objectives are to: 1) Perform developmental assessments on infants born to the SARS-CoV-2-infected cohort and uninfected controls, and 2) Explore associations between...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University a $382,657 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to investigate the serological and cellular immune responses to SARS-CoV-2 vaccination in pediatric multiple sclerosis patients receiving different immunotherapies. The key objectives are to:
Measure the antibody type, specificity, and neutralization ability in response to SARS-CoV-2 vaccination in pediatric multiple...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to identify patient characteristics, coinfecting viruses, microbial contributions, and host responses that impact disease severity in SARS-CoV-2-infected children. The $1,989,655 award to the Arkansas Children's Research Institute will leverage metagenomic sequencing to simultaneously evaluate viral and host genetic material from clinical...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,380,350 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Washington University in St. Louis. This 5-year project, titled "Mechanisms of Immune Protection Against Respiratory Viruses", focuses on defining the mechanisms of long-lived B cell and antibody responses to influenza and SARS-CoV-2 vaccines. The project has two main goals: (A) determining the...
This federal Project Grant award, valued at $502,075.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the impact of mucosal adjuvanted vaccines on virus transmission in preclinical animal models for SARS-CoV-2 and influenza virus infection. The research will compare the protection provided by intranasal mucosal adjuvanted vaccination versus intramuscular parenteral...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the role of the protein ADAM9 in the immune response to SARS-CoV-2 infection and its impact on COVID-19 disease pathogenesis. The $190,058 award, spanning from December 2024 to November 2029, will be executed by the University of Massachusetts Medical School to investigate the ADAM9/MDA5...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,452,000 Project Grant under CFDA 93.855 Allergy and Infectious Diseases Research to the University of Colorado-Denver. The grant supports the development of a "tunable nanophage platform" to rapidly screen and evaluate potential vaccine candidates against SARS-CoV-2 and other emerging infectious diseases. Key objectives include engineering next-generation nanophages that display viral spike protein...